How many years can I usually take Pazopanib tablets for maintenance treatment?

Pazopanib, also known as pazopanib, is an oral multi-target tyrosine kinase inhibitor commonly used in the treatment of solid tumors such as renal cell carcinoma and soft tissue sarcoma. Its main function is to inhibit tumor growth by inhibiting various receptors related to tumor angiogenesis, such as VEGFR, PDGFR and c-Kit. Pazopanib not only plays an important role in the initial stage of treatment, but is also often used in the maintenance stage of treatment to delay disease progression and improve patient survival rates.

The maintenance treatment time of pazopanib does not have a fixed number of years, and is usually determined based on the patient’s specific condition, disease response, and drug tolerance. Generally speaking, as long as the drug is still effective in controlling tumors and the patient does not experience serious adverse reactions, doctors will recommend that patients take it long-term. Clinically, many patients can continue to take pazopanib for 1 to 3 years or even longer if their condition is stable, and some individuals can take pazopanib for more than 5 years.

Of course, long-term maintenance treatment also requires regular evaluation of efficacy and side effects. Some patients may experience adverse reactions such as abnormal liver function, hypertension, hand-foot syndrome, and fatigue while taking the drug, which may affect the possibility of continued use. Therefore, during long-term use of pazopanib, patients are recommended to regularly review liver and kidney function, blood pressure and imaging examinations to ensure that the drug is both safe and effective. If significant side effects occur, the doctor may consider reducing the dose, discontinuing the medication, or changing the treatment plan.

In general, the maintenance treatment time of pazopanib is mainly determined by the individual condition. As long as the drug effect is still there and the adverse reactions are controllable, it can theoretically be used for a long time. For patients who hope to achieve long-term remission, pazopanib offers the possibility of stable tumor control, but the entire treatment process needs to be scientifically adjusted under the guidance of a doctor. Patients themselves should also pay close attention to physical changes and maintain good communication with their doctors to achieve the best treatment results.

References：https://www.votrient.com/